Similar companies
Income Statement (USD)
| Q1 '25 | QoQ | |
|---|---|---|
| Revenue | 33M | 152.1% |
| Gross Profit | 33M | 152.1% |
| Operating expense | 70M | 0.7% |
| Net Income | -31M | 38% |
| EBITDA | -35M | 35.8% |
Balance Sheet (USD)
| Q1 '25 | QoQ | |
|---|---|---|
| Total Assets | 614M | 5.1% |
| Total Liabilities | 141M | 8.7% |
| Total Equity | 474M | 4% |
| Shares Outstanding | 89M | 2.2% |
Cash Flow (USD)
| Q1 '25 | QoQ | |
|---|---|---|
| Cash from operations | -28M | 31.8% |
| Cash from investing | -48M | 263% |
| Cash from financing | 7,000 | 100% |
EPS
Financial Highlights for Verve Therapeutics in Q1 '25
Verve Therapeutics reported a revenue of 33M, which is a 152.1% change from the previous quarter. An increase in revenue typically indicates growing demand for the company's products or services. This positive change in revenue is a good sign, suggesting that the company's sales are moving in the right direction.
Gross Profit stood at 33M, marking a 152.1% change since the last quarter. Gross profit showcases the efficiency in production and sales processes.
Operating Expenses for this period were 70M, showing a 0.7% change from the last quarter. Operating expenses cover the costs of running daily business operations. A significant increase might indicate inefficiencies or investments in growth, while a decrease could suggest cost-saving measures or potential underinvestment in key areas.
Net Income for the quarter was -31M, showing a 38% change from the prior quarter. Net income provides a clear picture of the company's profitability after all expenses. An increase suggests the company is becoming more profitable, while a decrease may raise concerns about the company's financial health, unless there are specific one-time costs or investments.
The company's EBITDA for the quarter was -35M, showing a 35.8% change from the previous period. EBITDA gives insight into the company's operational profitability, excluding non-operating expenses like interest and taxes. A rising EBITDA indicates strong operational performance, while a declining EBITDA may signal operational challenges or increased costs.
It was a positive quarter for Verve Therapeutics with growth in revenue, gross profit, and net income. Higher operating expenses might indicate increased investments or potential inefficiencies.
